Improving the Management of Severe Asthma in Patients with Type 2 Inflammation
PULMONARY DISEASE
Improving the Management of Severe Asthma in Patients with Type 2 Inflammation
0.50 AMA PRA Category 1 Credit(s)™ 0.50 AANP Contact Hours 0.50 AAPA Category 1 Credit(s)
February 28, 2019
February 28, 2020
PRIMARY AUDIENCE:
Primary care physicians, NPs, PAs, and other clinicians who care for patients with asthma.
RELEVANT TERMS:
Asthma assessment, shared decision making
Nicola A. Hanania, MD, MS
Nicola A. Hanania, MD, MS
Associate Professor of Medicine
Pulmonary and Critical Care Medicine
Director, Airways Clinical Research Center
Baylor College of Medicine
Houston, TX
Reynold A. Panettieri, Jr., MD
Reynold A. Panettieri, Jr., MD
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Professor of Medicine, Robert Wood Johnson Medical School
Emeritus Professor of Medicine, University of Pennsylvania
Rutgers Institute for Translational Medicine and Science
New Brunswick, NJ
| 1. | Describe the role of Type 2 inflammation in asthma pathophysiology and the phenotypic and endotypic characterization of asthma with Type 2 inflammation. | 2. | Review the mechanism of action, efficacy, and safety of targeted agents approved for the management of severe, uncontrolled asthma with Type 2 inflammation and those in late-stage development. |
| 3. | Incorporate agents targeted at Type 2 inflammation into the management of appropriate patients with severe, uncontrolled asthma not responding to ICS and bronchodilator therapy. |
CONTINUING EDUCATION CREDIT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.25 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19023554. This activity was planned in accordance with AANP Accreditation Standards and Policies.
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid for one year from 02/28/2019. PAs should only claim credit commensurate with the extent of their participation.
DISCLOSURES
All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff and reviewers of MCM Education and Purdue University College of Pharmacy have no relationships to disclose.Dr. Hanania discloses the following:
Grants/research support: GSK, Boehringer-Ingelheim, AstraZeneca, Sanofi
Consultant: GSK, AstraZeneca, Sanofi, Novartis
Dr. Panettieri discloses the following:
Grants/research support: AstraZeneca, MedImmune, Research Institute of Fragrance Materials, OncoArendi, Equillium, Sienna Biopharmaceuticals
Consultant: AstraZeneca, MedImmune, Teva, Novartis, Boehringer-Ingelheim
Speakers bureau: AstraZeneca, MedImmune, Teva, Novartis, Boehringer-Ingelheim, Sanofi/Regeneron, Genentech
Advisory board: Equillium
Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.
DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
COMMERCIAL SUPPORT
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and aboveFor video playback, install the latest version of Flash or Quicktime. |
Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |